[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557280":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":28,"id":57,"slug":28,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":28,"enrollmentInfo":66,"targetDuration":28,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":28,"overallStatus":37,"whyStopped":28,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Monthly injection","EXPERIMENTAL","The patients will recive 12 intravitreal injections in one eye and 12 sham injections in the other eye each month",[13],"Procedure: Intravitreal injection of CB-PRP",{"label":15,"type":10,"description":16,"interventionNames":17},"Bimonthly injection","The patients will receive 6 intravitreal injections in one eye and 6 sham injections in the other eye each two months",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Quarterly injection","The patients will receive 4 intravitreal injections in one eye and 4 sham injections in the other eye each three months",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","Intravitreal injection of CB-PRP","The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP",[15,9,19],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Maria Cristina Savastano, MD, PhD","CONTACT","0630151","mariacristina.savastano@policlinicogemelli.it",[36],{"facility":5,"status":37,"city":38,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Rome","00168","Italy",{"type":42,"coordinates":43},"Point",[44,45],12.51133,41.89193,{"lat":45,"lon":44},[48,52],{"name":49,"role":32,"phone":50,"phoneExt":28,"email":51},"Maria Cristina Savastano","+39 3384443002","mariacristina.savastano@unicatt.it",{"name":49,"role":53,"phone":28,"phoneExt":28,"email":28},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Savastano Maria Cristina","MD, PhD","100557280",false,"NCT06536062","Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.","Age-related Macular Degeneration of Atrophic Type Treated With Intravitreal Injection of Umbilical Cord Blood Enriched With Platelet Plasma: Multicenter Study.","M-CORD IV","Inclusion Criteria:\n\n* Age ≥65 years\n* Bilateral dry-AMD\n* ETDRS-corrected visual acuity between (or equal to) 1\u002F10 and 4\u002F10\n* No concomitant ocular pathology (e.g., Glaucoma, amblyopia) or systemic pathology that would result in a BIAS for primary goal assessment\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 65 years\n* Pregnancy\n* Previous inflammatory\u002Finfectious events involving the eyes\n* Eye trauma, diabetes, or disease potentially damaging to the visual system, even in the absence of impairment at the time of intake\n* Previous intravitreal treatments.\n* Refusal to sign informed consent.","ALL","65 Years",{"count":67,"type":68},36,"ESTIMATED","INTERVENTIONAL",[71],"NA","The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD).",[74],"Dry Age-related Macular Degeneration","2025-09-17",{"date":77,"type":78},"2025-09-23","ACTUAL",{"date":80,"type":78},"2024-07-20",{"date":82,"type":68},"2026-07-30",{"name":5,"class":6},1]